Premium
Sarcoidosis during infliximab therapy for Crohn’s disease
Author(s) -
TAKAHASHI Hidetoshi,
KANETA Kazuhiro,
HONMA Masaru,
ISHIDAYAMAMOTO Akemi,
ASHIDA Tomonori,
KOHGO Yutaka,
OHSAKI Yoshinobu,
IIZUKA Hajime
Publication year - 2010
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.2010.00861.x
Subject(s) - infliximab , sarcoidosis , medicine , psoriasis , rheumatoid arthritis , disease , crohn's disease , dermatology , tumor necrosis factor alpha , inflammatory bowel disease , gastroenterology
Tumor necrosis factor‐α (TNF‐α) antagonists are effective for inflammatory diseases, such as Crohn’s disease, rheumatoid arthritis (RA) and psoriasis. Although TNF‐α antagonists are also useful for sarcoidosis, paradoxical occurrence of sarcoidosis or sarcoidal reaction may be observed. We report a Crohn’s disease patient, who developed sarcoidosis during infliximab therapy. A 35‐year‐old man had been receiving infliximab for 7 months for Crohn’s disease. He developed cough and fever, accompanied by an infiltrated erythematous plaque on his right knee. The chest radiography, skin biopsy and laboratory findings were all consistent with sarcoidosis.